Background: Vascular endothelial cells represent an important source of arachidonic acid (AA)-derived mediators involved in the generation of anti-or proatherogenic environments. Evidence emerged (in mast cells), that in addition to phospholipases, neutral lipid hydrolases as adipose triglyceride lipase (ATGL) also participate in this process. Objective: To examine the impact of ATGL on AA-release from cellular phospholipids (PL) and on prostacyclin secretion in human aortic endothelial cells (HAEC). Methods and results: siRNA-mediated silencing of ATGL promoted lipid droplet formation and TG accumulation in HAEC (nile red stain). ATGL knockdown decreased the basal and A23187 (calcium ionophore)-induced release of 14 C-AA from (
Introduction
The efficiency of prostanoid production is largely dependent on the activity of biosynthetic enzymes and the availability of arachidonic acid (AA) in cellular glycerolipid pools (Scott et al. 1982) . Stimulation of cells by various agonists leads to the release of AA from membrane phospholipids (PL) by phospholipase A2 (PLA2) enzymes, primarily Ca 2þ -dependent cytosolic PLA2IVA (cPLA2). While a portion of the released AA is converted into various eicosanoids, the remaining free AA is reacylated into PL and triglycerides (TG) (Triggiani et al. 1994) .
As found initially in adipose tissue, adipose triglyceride lipase (ATGL) catalyses the first, rate-limiting step in the hydrolysis of TG stored within intracellular lipid droplets, yielding free fatty acid and diacylglycerol (DG) (Zimmermann et al. 2004) . ATGL deficiency in mice is associated with massive lipid accumulation in tissues, severe skeletal-and cardiomyopathy and premature death, primarily due to heart failure (Haemmerle et al. 2006) . Humans with mutations in the ATGL gene suffer from neutral lipid storage disease (NLSD) characterised by severe myopathy and massive TG accumulation in most tissues (Fischer et al. 2007) . Lately, ATGL gained attention in the context of inflammation, when the lipase was described to regulate eicosanoid production in activated human mast cells and neutrophils (Dichlberger et al. 2014 , Schreiber and Zechner 2014 , Schlager et al. 2015 .
Importantly, also a functional role in endothelial cells (ATGL deficient mice exhibit severe endothelial dysfunction) (Schrammel et al. 2014) and in the pathogenesis of atherosclerosis was attributed to ATGL. Decreased expression of ATGL in the obese insulin-resistant state (Jocken et al. 2007 , Steinberg et al. 2007 ) (a pathological condition accompanied with increased incidence of atherosclerosis), as well as increased expression of adhesion molecules in ATGL depleted human aortic endothelial cells (HAEC), indicates a significant role of ATGL in endothelial inflammatory processes as well (Inoue et al. 2011) .
Based on the fact that provision of AA is a basic prerequisite for the biogenesis of many pro-and anti-inflammatory mediators and on the observation that stimulus-induced AA release from cellular PL is often dependent on TG-derived AA (Triggiani et al. 1994) , we aimed to examine the role of ATGL in human endothelial cells -focusing on stimulusinduced AA release and on prostacyclin secretion (as a representative anti-inflammatory prostanoid).
Materials and methods

Cell culture
Human primary aortic endothelial cells were obtained from Lonza (Cologne, Germany) and maintained in endothelial cell growth medium [EGM-MV Bullet Kit ¼ EBM medium þ growth supplements þ FCS (Lonza)] supplemented with 50 IU/ml penicillin, and 50 lg/ml streptomycin. Cells were cultured in gelatine-coated dishes at 37 C in a 5% CO 2 humidified atmosphere and were used for experiments from passage 5 to 10.
Si-RNA mediated knockdown of ATGL To create ATGL knockdown cells and respective controls, cells were transfected with siRNA against ATGL (Qiagen, Hilden, Germany) or predesigned control siRNAs (Qiagen, AllStars Negative Control siRNA) and PrimeFect-siRNA transfection reagent (Lonza, Cologne, Germany). In brief, one day after seeding (50,000 cells/12-well), the medium was switched to 500 ll serum-free medium. Two microlitres of PrimeFect was diluted in 101 ll of dilution buffer and incubated for 15 min. Thereafter, 15 ll of the corresponding siRNA (1 lM) was added to the PrimeFect mixture and incubated for further 15 min. The lipid-RNA complexes were applied to the cell supernatant for 3 h, followed by the addition of serumcontaining medium on top. Cells were used for experiments 48 h after siRNA transfection.
Quantitative real-time PCR (qRT-PCR)
RNA isolation and qRT-PCR were performed using ATGL (Primer Assay QT00019754) and beta-2-microglobulin (Primer Assay QT01665006) primers, exactly as described (Riederer et al. 2010) .
Western blotting
Western blots were performed as described (Riederer et al. 2010) . Briefly, HAEC transfected with ATGL siRNA or negative control siRNA, were washed with PBS and collected in 50 ll/ well loading buffer [20% (w/v) glycerol, 5% (w/v) SDS, 0.15% (w/v) bromophenol blue, 63 mmol/I Tris-HCl, pH 6.8, and 5% (v/v) b-mercaptoethanol] followed by boiling for 10 min. Forty microliters of the lysate were subjected to each lane and analysed by SDS-PAGE (10% gel) and subsequent immunoblotting using an ATGL-specific antibody (Cell Signaling Technology, Beverly, MA) and a HRP-labelled antirabbit secondary antibody. Protein signals were detected by an enhanced chemiluminescent substrate for detection of HRP (SuperSignal West Pico or Femto, Thermo Scientific, Rockford, IL). Blots were re-probed with actin antibody (Oncogene).
14 C-AA release HAEC were transfected with siRNA and labelled with 14 C-AA (4 lM, spec. activity 58 mCi/mmol) in complete medium for 20 h. Unbound 14 C-AA was removed by excessive washing in PBS supplemented with 1% BSA. Following incubation in serum-free medium for 7 h, cells were incubated with or without A23187 (1 lM) in the presence of 0.03% BSA for 10 min. Cell media were collected, spun to remove cells and immediately frozen at -70 C until extraction. Cells were washed with PBS and lysed in 0.3 M NaOH/0.1% SDS.
The amounts of 14 C-AA released into medium were detected by thin-layer chromatography, quantified by densitometry and normalised to total cellular radioactivity measured by scintillation counting of cell lysates exactly as described. Results of this relative quantification are described in arbitrary units (AU) (Riederer et al. 2010) .
Quantification of 14 C-PL, and -TG by thin layer chromatography (TLC)
For the determination of the 14 C-AA content in total PL and TG, HAEC were labelled as described above. Cell layers were extracted with two volumes of hexane/isopropanol (3:2, v/v), evaporated in the SpeedVac and redissolved in chloroform before application onto TLC plates. For separation of total 14 C-PL and 14 C-TG, hexane-diethylether-glacial acetic acid (70:29:1; v/v/v) was used as the mobile phase. The signals corresponding to 14 C-PL, and -TG, were visualised upon exposure of the TLC plates to a tritium screen (GE Healthcare, Little Chalfont, UK) on the STORM imager. Relative quantification was performed by densitometric volume report analysis and results were normalised to total cellular radioactivity (measured by scintillation counting of cell lysates) and expressed as AU.
Nile red stain ATGL-silenced or control HAEC were incubated with Nile Red (100 ng/ml) for 15 min. Lipid staining was evaluated by fluorescence microscopy.
Lipid extraction and mass spectrometry of TG
The cell layer of one 12-well (150,000 cells) was extracted according to Bligh and Dyer (1959) and dried under a stream of nitrogen. Acquisition of TG species was performed on a LTQ-FT in FT full scan mode at a resolution of 200,000 (Fauland et al. 2011) . TG were quantified by using the Lipid Data Analyzer (Hartler et al. 2011) , and shown as results relative to the total amount of selected molecules per 150,000 cells -depicted as AU.
Measurement of 6-keto-PGF1a
Following incubation in serum-free medium for 7 h, siRNA transfected cells were incubated with or without A23187 (1 lM) in the presence of 0.03% BSA for 10 min. Cell media were collected, spun to remove cells and immediately frozen at -70 C until extraction. 6-Keto PGF1a was measured in cell culture media by an EIA kit (Cayman, Ann Arbor, MI) according to the manufacturer's protocol and was normalised to cellular protein content (BCA, Pierce, Rockford, IL).
Statistical analysis
Cell culture experiments were performed at least three times and values are expressed as mean ± STD. Data were analysed by Student's t-test or one-way analysis of variance and the Bonferroni post hoc test. Group differences were considered significant for p < .05 ( Ã ).
Results
ATGL knockdown increases TG content in HAEC
To address the role of ATGL in endothelial inflammatory processes, ATGL was silenced in HAEC by transfection with siRNA. Compared with control HAEC (transfected with negative control siRNA), ATGL silenced HAEC exhibited markedly decreased both ATGL mRNA (Figure 1(A) ) and protein levels (Figure 1(A) inset) . This was accompanied by a massive accumulation of Nile-red stained lipid droplets (Figure 1(B) ) and an increase in total TG content (Figure 1(C) ).
ATGL knockdown decreases 14 C-AA release in HAEC
To investigate the capability of AA release, 14 C-AA labelled HAEC were tested under basal conditions as well as after 10 min stimulation with the calcium ionophore A23187. As shown in Figure 2 (A), basal as well as A23187-induced 14 C-AA release was significantly lower in ATGL silenced, compared with control cells.
C-AA-PL content is decreased in ATGL silenced cells upon A23187 stimulation
To clarify the observed decrease in 14 C-AA release ( Figure  2(A) ), the levels of 14 C-AA were determined in the PL pool of the corresponding cell lysates, following a 20-h labelling with 14 C-AA release, 14 C-AA content in PL and 6-keto PGF1a secretion are decreased in ATGL silenced cells. (A) 14 C-AA release: After transfection with ATGL siRNA or negative control siRNA, HAEC were labelled with 14 C-AA for 20 h. After extensive washing, HAEC were further incubated in serum-free medium for 7 h, followed by incubation with or without A23187 in serum-free medium containing 0.03% BSA for 10 min. Lipid extracts of cell media were separated by TLC followed by densitometric quantification of 14 C-AA-spots. The amounts of 14 C-AA released into medium were normalised to total cellular radioactivity measured by scintillation counting of cell lysates and expressed as arbitrary units (AU). (C) 14 C-AA content in PL: Lipid extracts of cells treated as described in (A) were separated by TLC followed by densitometric quantification of 14 C-PL-spots. Results are mean ± STD. (B) 6-keto PGF1a-secretion: siRNA transfected HAEC were treated as in A (without AA-labelling). 6-Keto PGF1a was determined in cell culture supernatants by EIA and normalised to cellular protein content. Results are mean ± STD.
14 C-AA and a 10-min incubation under basal and A23187 stimulated conditions, respectively. While the 14 C-AA levels in PL were not affected by ATGL silencing under basal conditions, they were significantly decreased upon A23187-stimulation (in ATGL silenced but not in control cells) (Figure 2(C) ).
6-Keto-PGF1a secretion is decreased in ATGL silenced HAEC
Addressing the role of ATGL in endothelial prostanoid production, 6-keto PGF1a secretion (an endothelial secretagogue and stable hydrolysis product of prostacyclin) was measured by EIA. Under basal conditions, values were beyond the detection limit. But upon stimulation with A23187, ATGLsilenced cells exhibited decreased secretion of 6-keto PGF1a (Figure 2(B) ).
Discussion
Here we show for the first time that the efficiency of basal and stimulus-induced AA release in vascular endothelial cells is dependent on ATGL. Based on the current literature, ATGL is a single-compartment-acting enzyme that exerts its activity on TG in lipid droplets only. The observed 14 C-AA depletion in PL of A23187-stimulated ATGL knockdown cells points towards the role of ATGL and the cellular TG-pool in the replenishment of the PL-pool with AA. This is in line with previous pulse-chase studies in lung macrophages demonstrating a flux of AA from the TG-into the PL-pool (Triggiani et al. 1994) . Even the basal AA release was decreased in ATGL-silenced cells (Figure 2(A) ), suggesting the involvement of ATGL in the remodelling of membrane PL (which might also or additionally be attributed to the minor phospholipase activity of ATGL (Notari et al. 2006 , Kanno et al. 2013 , or a decreased cPLA2 activity, which was not addressed in this study). In membrane PL remodelling processes, AA is cleaved from PL by primarily Ca 2þ -independent group VI PLA2 (iPLA2) and reincorporated back into PL by acyltransferases and transacylases (P erez-Chac on et al. 2009) ( Figure 3) . As described previously, the TG-pool was found to serve as a re-acylation pool for AA released from cellular PL upon stimulation of cPLA2 (Triggiani et al. 1994) . However, in our study, the 14 C-AA content in the TG-pool of A23187-stimulated control cells was not significantly increased, compared with unstimulated control cells (supplementary Figure 1 ). This discrepancy might be explained by the presence of BSA, a potent acceptor for released AA, in cell media in our experimental model, in contrast to BSA-free incubations described by Triggiani et al. (1994) . Considering co-localisation of ATGL and enzymes involved in eicosanoid production on lipid droplets (Brasaemle et al. 2004) , our study highlights ATGL as a potential new player in the endothelial eicosanoid-synthesising machinery (Figure 3 ). In line with our findings in HAEC, ATGL likewise seems to be a missing link in the well-established interplay between TGand PL-pools and the mobilisation of TG-associated AA for eicosanoid production in human inflammatory cells (Triggiani et al. 1994 , Wan et al. 2007 , Bozza et al. 2011 , Dichlberger et al. 2011 , Dichlberger et al. 2014 .
Concerning the severe endothelial dysfunction discovered in ATGL deficient mice (Schrammel et al. 2014) , the here described alteration of AA release and prostanoid production could also play a role in the dysbalance of endotheliumderived relaxing and contracting factors.
In the context of atherosclerosis, Inoue already showed that ATGL-knockdown leads to enhanced ICAM-1 expression and subsequently enhanced monocyte adhesion to HAEC (mediated by PKC-dependent activation of nuclear factorkappa-B) (Inoue et al. 2011) . As ICAM-1 upregulation is also known to be dependent on cPLA2 and eicosanoids (Hadad et al. 2011) , and based on the here described novel role of ATGL in AA-release and prostacyclin secretion, an increased incidence of atherosclerosis in obese insulin-resistant patients (with decreased ATGL) (Jocken et al. 2007 ) might at least in part be attributed to altered eicosanoid production by vascular endothelial cells.
Disclosure statement
The authors report no conflicts of interest. The authors alone are responsible for the content and writing of this article.
Funding
This work was supported by the Austrian Science Fund (FWF; grant P19473-B05 to S.F.) and the Frank Lanyar Foundation of the Medical University Graz, Austria (http://www.medunigraz.at/franz-lanyar-stiftung/) (grant 369 to S.F.).
The funding sources had no involvement in study design; collection, analysis and interpretation of data; in the writing of the report; and in the decision to submit the article for publication. In addition to the release of AA from PL stores (e.g. by the action of cPLA2, iPLA2, PLC, and ATGL phospholipase), our data provide evidence that AA is also released from TG pools (by ATGL) and might be directly metabolised to prostaglandins (by the action of COX enzymes). Alternatively, and especially evident upon stimulation with A23187, ATGL releases AA which is reincorporated into the PL pool (by the Kennedy pathway or the Lands cycle, respectively). Thus ATGL seems to be involved in the replenishment of the PL pool with AA.
